MedChemComm

RESEARCH ARTICLE

View Article Online
View Journal | View Issue

Check for updates

Cite this: *Med. Chem. Commun.*, 2018, **9**, 1305

Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease†

Sang Won Park,‡[a] Suhrid Banskota,‡[b] Pallavi Gurung,[b] You Jin Jin,[a] Han-eol Kang,[a] Chhabi Lal Chaudhary,[b] Sang Yeul Lee,[a] Byeong-Seon Jeong,*[b] Jung-Ae Kim *[b] and Tae-gyu Nam *[a]

Received 21st March 2018,
Accepted 2nd June 2018

DOI: 10.1039/c8md00156a

rsc.li/medchemcomm

Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract with complex pathogenesis. Here, we synthesized 6-heteroarylamino analogues to inhibit TNF-α-induced adhesion of monocytes to colon epithelial cells which are implicated in the initial inflammation process of IBD. The best analogue, **16a**, showed IC_{50} = 0.29 μM, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA), a positive control. Oral administration of **6f** and **16a** dramatically ameliorated 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation in rat. The ameliorating effects were accompanied by a high level of recovery in colon and body weights and in the myeloperoxidase (MPO) level. Consistently, the compounds suppressed the expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein 1 (MCP-1). Moreover, they significantly suppressed the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while increasing the level of IL-10, an anti-inflammatory cytokine.

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.

Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory pathology occurring in the gastrointestinal tract with major subtypes being Crohn's disease and ulcerative colitis.[1] Although it is considered a low-mortality disease, it can severely devastate the quality of life of patients. It is spreading around the world with over 1 million people in the USA and 2.5 million in Europe being estimated to have IBD.[2] Recently, unprecedented growing rates have been observed even in traditionally low-incidence regions including developing countries. Several drugs are currently used in the clinic to treat symptoms of IBD.[2–4]

Although the causes of IBD have not been clearly understood, it is believed that complex association of genetic, environmental, and immune factors underlies the disease.[1,5] In the gut, the mucosal layer performs a first-line defense conducting a number of innate immune functions. Under harmful conditions such as disturbance of microbiotic and cytokine balance, intestinal epithelial cells participate in the initiation and dissemination of inflammation by secreting pro-inflammatory cytokines and chemokines.[5] Among them, tumor necrosis factor-α (TNF-α) is secreted from monocytes and colon epithelial cells. TNF-α, in turn, induces colon epithelial cells to express other inflammatory cytokines and adhesion molecules at a higher level. It recruits more inflammatory cells, including immune cells, to the damaged intestinal epithelium. This process is one of the critical steps in the initiation of inflammation and tissue injury in IBD.[6,7]

Besides TNF-α, other pro-inflammatory cytokines also contribute to the aggravation of colitis. Interleukin-6 (IL-6) plays a crucial role in the uncontrolled intestinal inflammatory process by enhancing STAT-3 nuclear translocation where it induces anti-apoptotic genes such as Bcl-xL. The development of T cells' resistance to apoptosis further aggravates intestinal inflammation.[8] The IL-1β level is increased in colonic tissues of IBD patients,[9] and its levels are positively linked with the disease severity of IBD.[10] In contrast to the enhanced pro-inflammatory cytokines, a decrease in IL-10, an anti-inflammatory cytokine mainly produced by innate immune cells such as monocytes and regulatory T cells, also

[a] *Department of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea. E-mail: tnam@hanyang.ac.kr; Fax: +82 31 400 5958; Tel: +82 31 400 5807*
[b] *College of Pharmacy and Institute for Drug Research, Yeungnam University, Gyeongsan 38541, Republic of Korea. E-mail: jeongb@ynu.ac.kr, jakim@yu.ac.kr; Fax: +82 53 810 4654; Tel: +82 53 810 2814, +82 53 810 2816*

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8md00156a

‡ Equally contributed as first authors.

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.

aggravates IBD[11] by losing its ability to inhibit bacterial product-mediated induction of pro-inflammatory cytokines, such as TNF-α and IL-1β.[12] Considering these networks and interactions between pro- and anti-inflammatory cytokines, a compound that corrects or restores the altered balance between the pro- and anti-inflammatory cytokines in IBD would be the most desirable therapeutic drug.

Although several molecular targets have been proposed for IBD,[13–16] TNF-α currently seems to be the most successful target mainly because of the high efficacy of anti-TNF-α monoclonal antibodies, such as infliximab and adalimumab. As virtually no small molecule has been approved for IBD since the anti-TNF-α antibodies, there are huge unmet medical needs for the chemical version of anti-IBD agents. A few small molecule anti-IBD agents have been reported in the literature or in clinical trials.[14,17–20]

We have previously reported the inhibitory activity of 6-alkyl- and 6-phenyl-amino-2,4,5-trimethylpyridin-3-ols against colitis.[21] Some of them inhibited TNF-α-induced monocyte adhesion to colon epithelial cells better than 5-aminosalicylic acid (5-ASA a.k.a. mesalazine), a positive control and the active metabolite of sulfasalazine (SSZ) which is a medication used for the treatment of IBD. Oral administration of the best compound showed about 30-times better efficacy than sulfasalazine, a prodrug of 5-ASA, in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis,[25] a widely used animal model of IBD.

In this study, we further expanded the scope of the side chain (HetAr group in Scheme 1) by installing heteroarylamino groups on the C(6)-position to achieve higher polarity. In fact, the clog*P* values of heteroaryl compounds shown here are smaller than those of the corresponding phenyl analogues by about one unit. The compounds shown here inhibited TNF-α-induced adhesion of monocytes to HT-29 human colonic epithelial cells.[22–24] In order to demonstrate *in vivo* efficacy, selected compounds were tested in the rat model of TNBS-induced colitis. The mode of action of the anti-colitis activities was further characterized by the relevant molecules *in vivo*.



Scheme 1 Synthetic scheme and structures of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols (**6**). Reagents and conditions: (a) $SOCl_2$, DMF, reflux, 30 min, 93%; (b) Zn, AcOH, reflux, 3 h, 92%; (c) DBDMH, THF, r.t., 3 h, 80%; (d) $PhCH_2Cl$, K_2CO_3, DMF, r.t., 12 h, 97%; (e) H_2N–HetAr (**4**), $Pd_2(dba)_3$, BINAP, NaO^tBu, toluene, reflux or $H_2NHetAr$ (**4**), $Pd(OAc)_2$, xantphos, Cs_2CO_3, toluene, reflux; (f) H_2, Pd/C, MeOH, r.t. or BCl_3, CH_2Cl_2, r.t.

Results and discussion

Synthesis

6-Heteroarylamino-2,4,5-trimethylpyridin-3-ols (**6a–6q**) were synthesized using a synthetic route we have developed (Scheme 1)[26] but with novel heteroarylamines **4**. In short, $SOCl_2$ with a catalytic amount of DMF converted two primary hydroxy groups of pyridoxine·HCl (**1**) to chlorides which were then removed reductively using Zn and acetic acid under refluxing conditions to give 2,4,5-trimethylpyridin-3-ol. The C(6)-position was brominated by electrophilic aromatic bromination with 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) to afford compound **2** and the phenolic OH group was then protected with a benzyl group to give compound **3**. Bromide in compound **3** was replaced with various heteroarylamines **4** under Buchwald–Hartwig amination reaction conditions to afford compounds **5**. Lastly, the benzyl protective group was removed either by catalytic hydrogenolysis or by BCl_3 depending on the substituents to give 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols (**6a–6q**).

In cases of 6-(1,3,4-oxadiazol-2-yl)amino analogues **15** and 6-(1,3,4-thiadiazol-2-yl)amino analogues **16**, the oxadiazole and thiadiazole groups did not survive the debenzylation conditions used in the final step of Scheme 1. Therefore, we introduced a *tert*-butyldiphenylsilyl (TBDPS) group instead of a benzyl group for the protection of the phenolic OH of compound **2** (Scheme 2). TBDPS-protected compound **7** was coupled with benzophenone imine, a synthetic equivalent of ammonia, under Buchwald–Hartwig amination reaction conditions to give **8**. The free primary amino group was liberated from the imine of **8** by acidic methanolysis to afford compound **9** which was then treated with thiophosgene and Hünig's base to give isothiocyanate **10**. Treatment of **10** with various *N*-acylhydrazides **11** leads to the corresponding *N*-acyl thiosemicarbazides **12** which serve as key intermediates for the preparation of both 2-amino-1,3,4-oxadiazoles (**13**) and 2-amino-1,3,4-thiadiazoles (**14**).[27] A desulfurative cyclization method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was successfully employed for the preparation of

 This journal is © The Royal Society of Chemistry 2018

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.



Scheme 2 Synthesis of 6-(1,3,4-oxadiazol-2-yl)amino analogues (**15**) and 6-(1,3,4-thiadiazol-2-yl)amino analogues (**16**). Reagents and conditions: (a) TBDPSCl, imidazole, DMF, r.t., 24 h, 87%; (b) $Ph_2C{=}NH$, $Pd_2(dba)_3$, BINAP, NaO^tBu, toluene, reflux, 5 h, 89%; (c) HCl–MeOH, THF–MeOH, r.t. 24 h, 93%; (d) $CSCl_2$, $^iPr_2NEt$, r.t., 1 h, 98%; (e) CH_2Cl_2, r.t.; (f) EDCI, DMSO, 60 °C; (g) *n*-Bu_4NF, THF, 0 °C; (h) *p*-TsCl, Et_3N, NMP, r.t.

6-(1,3,4-oxadiazol-2-yl)amino analogues **13**. On the other hand, an efficient reaction system (*i.e.*, *p*-toluenesulfonyl chloride (*p*-TsCl) with triethylamine in a polar solvent, *N*-methyl-2-pyrrolidine (NMP)) for dehydrative cyclization of **12** gave 6-(1,3,4-thiadiazol-2-yl)amino compounds **14**. Finally, deprotection of TBDPS of the cyclized compounds **13** and **14** with tetra-*n*-butylammonium fluoride afforded oxadiazole/thiadiazole-containing pyridinol compounds **15** and **16**, respectively.

Inhibition of TNF-α-induced cell adhesion

TNF-α-induced attachment and infiltration of immune cells to colon epithelium is one of the hallmark events leading to IBD.[6,7] To quantitatively assess the inhibitory activity of the compounds against this adhesion process, we set up a cell-based screening system in which monocytes (U937 cells) and colon epithelial cells (HT-29 cells) were co-cultured in the presence of TNF-α.[26] Treatment of TNF-α indeed induced the adhesion of monocytic cells to colonic epithelial cells, indicated by increased fluorescence that was pre-loaded in U937 cells (ESI†). 5-ASA showed very weak inhibition (3.5%) at 1 μM concentration and only moderate inhibition (50.5%) even at 20 mM against the adhesion (Table 1). Meanwhile, 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols (**6**, **15** and **16**) exerted up to 78% inhibition at 1 μM, equivalent to three to five orders of magnitude stronger activities than that of 5-ASA. Of note, 1 μM concentration of compounds **6f**, **6k**, and **16a** showed superior activity to 20 mM 5-ASA.

2-Pyridyl analogue **6a** showed little activity (8.5%) compared to its phenyl analogue (73.6%) published by us[21] in the inhibition of TNF-α-induced adhesion. However, installation of a $-CF_3$ group on the *m*-position of the 2-pyridyl group (**6b**) increased the activity by 2.7-fold from **6a**, while the same group on the *para*-position increased the activity by 4.1-fold (**6c**). Interestingly, with the identical *p*-CF_3 substituent, the 3-pyridyl analogue (**6d**) showed a 6.0-fold higher activity than **6a**. Replacement of the *p*-CF_3 group of **6c** with weaker electron-withdrawing *p*-Cl increased the activity to 59.0% (**6e**). Upon the change of 2-pyridyl substitution of **6e** to the 3-pyridyl position with the same *p*-Cl (**6f**), the activity reached the highest point (75.4%). Among the pyridine and quinoline analogues (**6a–6l**), analogues that can assist a cyclic hydrogen bond network with or without H_2O between

Table 1 Inhibitory activity against TNF-α-induced monocyte adhesion to colon epithelial cells

Comp.	Inhibition (%)[a]
5-ASA (1 μM)	3.5 ± 2.4[b]
5-ASA (20 mM)	50.5 ± 1.8[b]
6a	8.5 ± 1.2[b]
6b	22.8 ± 10.9
6c	34.8 ± 16.3
6d	50.6 ± 10.6[b]
6e	59.0 ± 8.4[b]
6f	75.4 ± 3.4[b]
6g	60.2 ± 5.8[b]
6h	55.4 ± 4.5[b]
6i	10.4 ± 5.9
6j	52.8 ± 6.9[b]
6k	63.4 ± 1.6[b]
6l	56.6 ± 1.1[b]
6m	31.9 ± 6.4[b]
6n	23.7 ± 2.4[b]
6o	23.7 ± 6.1[b]
6p	38.5 ± 1.3[b]
6q	59.9 ± 4.7[b]
15a	26.2 ± 4.6[b]
15b	35.8 ± 5.0[b]
15c	1.4 ± 3.0
15d	55.7 ± 4.9[b]
16a	78.7 ± 2.5[b]
16b	13.7 ± 2.3[b]
16c	13.2 ± 1.9[b]
16d	16.6 ± 3.1[b]
16e	52.3 ± 1.1[b]

[a] Data are represented as inhibition % at 1 μM concentration of the compound and as mean ± SEM. All experiments were independently carried out at least three times. [b] $P < 0.05$ compared to the vehicle-treated control group.

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.

the C(6)-amino group and the heteroaryl group (*e.g.*, **6c** and **6e**) generally showed lower activity than their counterparts that have unfavorable structure for the cyclic network (*e.g.*, **6d** and **6f**). Quinoline analogues, **6g–6l**, showed the same trend; **6i** being the only one that possibly forms the cyclic hydrogen bond showed marginal activity (10.4%) while the rest of the quinolone analogues showed several-fold higher activity (52.8–63.4%).



Indole (**6m**), thiophene (**6n**), thiazole (**6o**) and oxazole (**6p**) analogues showed a modest range of activities while the benzimidazole analogue (**6q**) showed high activity (59.9%). Next, we decided to explore the 1,3,4-oxadiazole (**15**) and 1,3,4-thiadiazole (**16**) series which have three heteroatoms in the cycles. Among the oxadiazole series (**15**), the *p*-trifluoromethylphenyl analogue (**15d**) showed the highest activity (55.7%) while the rest showed low to modest activity. Of the thiadiazoles (**16**), the simplest phenyl substitution (**16a**) showed tremendously high activity (78.7%). There seems to be no clear structure–activity relationship (SAR) among this series in terms of the electronic effect of the substitution. Although the electron-withdrawing substitution (**16e**) is more active than the electron-donating substitution (**16c**), neither of the compounds is more active than the phenyl substitution (**16a**). We then measured the half maximal inhibitory concentration (IC_{50}, μM) of three representative compounds: **6f**, **6k**, and **16a**, whose activities are aligned in a narrow range in a high activity group in Table 1. As shown in Fig. 1, their IC_{50} values turned out to be 0.36, 0.54 and 0.29 μM, respectively. The order of their IC_{50} values is exactly consistent with that of a single concentration cell-based assay, demonstrating a high degree of correlation between the assays and the validity of our methodology. The best IC_{50} is up to about 7×10^4-fold better than that of 5-ASA ($IC_{50} \approx 20$ mM).



Fig. 1 IC_{50} values of the selected compounds, **6f**, **6k** and **16a**. Each data represents mean ± S.E.M for three independent experiments performed in triplicate.

In vivo activity against a TNBS-induced colitis model and the mode of action

Next, we used a TNBS-induced rat colitis model to assess the anti-colitis activity *in vivo*. We chose two compounds that showed the best activity in Table 1 for this assay, **6f** and **16a**, which represent distinctive heterocyclic scaffolds. As a macroscopic marker to represent a disease phenotype, we measured the recovery level in colon and body weights upon drug treatment. Upon rectal administration of TNBS, the rats showed signs of colitis, such as bloody diarrhea, and wasting conditions with sluggish and weak movement.[27] Compared to the rats in the sham-operated group, the TNBS-treated rats showed a significant reduction in body weight, followed by a lagging increase. In contrast, rats receiving oral administration of **6f** or **16a** (1 mg kg^{-1}) showed significant recovery of the TNBS-induced decrease in body weight (Fig. 2A). Besides, **16a** showed 79% recovery in colon weight at 1 mg kg^{-1} dose, which has superior macroscopic activity to SSZ (300 mg kg^{-1}), **6f** and our previous compound[21] which showed about 72% recovery in colon weight at 1 mg kg^{-1} dose, demonstrating the significant efficacy of the new scaffold (Fig. 2C). Colon tissues in the TNBS-treated lesion site showed significant inflammation, as revealed by edema and adhesion in gross morphology examination (Fig. 2B), and increased wet weight per colon length (Fig. 2C). In addition, the myeloperoxidase (MPO) level in colon tissues is directly related to neutrophil infiltration into tissues, serving as a biochemical marker of inflammation.[28,29] TNBS treatment induced a tremendous increase in MPO activity (Fig. 2D), and the increased MPO activity by TNBS (456.67 ± 41.78 ng mL^{-1}) was significantly suppressed by treatment with **6f** (127.02 ± 19.24 ng mL^{-1}) and **16a** (107.37 ± 14.09 ng mL^{-1}). The inhibitory effect of these compounds at 1 mg kg^{-1} was better than that of 300 mg kg^{-1} SSZ (MPO level of 209.65 ± 4.13) (Fig. 2D).

Although the fundamental molecular targets of the compounds responsible for the phenotype are yet to be investigated, we further examined in this study the inhibitory effects of the compounds on the expression levels of cytokines responsible for the inflammatory response. It will provide more consistency to our mechanism based on the assay against TNF-α-induced cell adhesion. In ELISA (Fig. 2E) and western blotting (Fig. 2F–I) analyses, TNBS treatment dramatically increased the expression of monocyte chemoattractant-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and pro-inflammatory cytokines, TNF-α, IL-1β and IL-6, whereas anti-inflammatory cytokine, IL-10, was significantly decreased in the inflamed colon tissues (Fig. 2F and I). However, oral administration of **6f** or **16a** significantly restored the TNBS-altered protein expressions. All these changes consistently and strongly support the anti-IBD activity of our compounds. Indeed, the inhibitory effect of 1 mg kg^{-1} **6f** or **16a** was much

 This journal is © The Royal Society of Chemistry 2018

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.



Fig. 2 6-Heteroarylamino-2,4,5-trimethylpyridin-3-ol (**6f** and **16a**) ameliorates the clinical features of TNBS-induced colitis in rats. Colitis was induced by rectal administration of TNBS. The control group received 50% ethanol as a vehicle. Data represent the mean ± SEM for five rats per group. $^{*}P < 0.05$ compared to the vehicle-treated control group. $^{\#}P < 0.05$ compared to the TNBS-treated group. (A) Macroscopic appearance of the large intestine. (B) Body weight was recorded daily from day 0 to day 5. (C) Colon weight per unit length of the colon (distal 5–6 cm segment). (D) MPO activity of colon tissue measured with an MPO assay kit. (E) Expression of MCP-1 of colon tissue. (F–I) Inhibitory effects of compounds **6f** and **16a** on TNBS-altered protein expressions of TNF-α, IL-1β, IL-6, IL-10, and ICAM-1 in rat colon tissues. The bar diagrams, G–I, represent the quantitative change in the expressions of the proteins. $^{*}P < 0.05$ *vs.* the vehicle-treated controls. $^{\#}P < 0.05$ *vs.* the TNBS-treated group.

stronger than that of 300 mg kg^{-1} SSZ. We believe that the data in this report also confirmed the validity of our phenotypic screening where the inhibitory activity of the compounds against the pathological role of TNF-α can be monitored.

Conclusions

We synthesized 6-heteroarylamino-2,4,5,-trimethylpyridin-3-ols and tested them as anti-colitis agents *in vitro* and *in vivo*. Most analogues showed superior inhibition to 5-ASA against TNF-α-induced adhesion of monocytes to colon epithelial cells at $>10^3$-fold lower concentration. In the TNBS-induced *in vivo* rat colitis model, oral administration of 1 mg kg^{-1} **16a** showed the most active recovery profiles in the body and colon weights among the aminopyridinol series including the 6-alkylamino and 6-phenylamino analogues we previously reported. The activity was also demonstrated by a significant decrease of MPO activity. In addition, **16a** significantly decreased the expression of inflammatory molecules and pro-inflammatory cytokines while increasing that of the anti-inflammatory cytokine. The effects of 1 mg kg^{-1} dose of **6f** and **16a** were much stronger than 300 mg kg^{-1} SSZ in these profiles, demonstrating their remarkable potency. Although the detailed mechanism of action should be studied further, it is strongly suggested that 6-heteroaylamino-2,4,5-trimethylpyridin-3-ol can be an excellent anti-IBD scaffold.

Conflicts of interest

The authors declare no competing interest.

Acknowledgements

This work was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI15C0542).

References

1 B. Khor, A. Gardet and R. J. Xavier, *Nature*, 2011, **474**, 307.
2 G. G. Kaplan, *Nat. Rev. Gastroenterol. Hepatol.*, 2015, **12**, 720.
3 M. F. Neurath, *Nat. Rev. Gastroenterol. Hepatol.*, 2017, **14**, 269.
4 I. Bravata, M. Allocca, G. Fiorino and S. Danese, *Curr. Opin. Pharmacol.*, 2015, **25**, 67.
5 T. Kucharzik, C. Maaser, A. Lugering, M. Kagnoff, L. Mayer, S. Targan and W. Domschke, *Inflammatory Bowel Dis.*, 2006, **12**, 1068.
6 C. M. Olesen, M. Coskun, L. Peyrin-Biroulet and O. H. Nielsen, *Pharmacol. Ther.*, 2016, **159**, 110.
7 G. Kojouharoff, W. Hans, F. Obemeier, D. N. Mannel, T. Andus, J. Scholmerich, V. Gross and W. Falk, *Clin. Exp. Immunol.*, 1997, **107**, 353.
8 R. Atreya and M. F. Neurath, *Clin. Rev. Allergy Immunol.*, 2005, **28**, 187.

Published on 08 June 2018. Downloaded by RSC Internal on 8/17/2018 10:11:00 AM.

9 M. Ligumsky, P. L. Simon, F. Karmeli and D. Rachmilewitz, *Gut*, 1990, **31**, 686.
10 M. Coccia, O. J. Harrison, C. Schiering, M. J. Asquith, B. Becher, F. Powrie and K. J. Maloy, *J. Exp. Med.*, 2012, **209**, 1595.
11 E. O. Glocker, D. Kotlarz, C. Klein, N. Shah and B. Grimbacher, *Ann. N. Y. Acad. Sci.*, 2011, **1246**, 102.
12 K. N. Couper, D. G. Blount and E. M. Riley, *J. Immunol.*, 2008, **180**, 5771.
13 L. Peyrin-Biroulet, W. Sandborn and B. E. Sands, *et al.*, *Am. J. Gastroenterol.*, 2015, **110**, 1324.
14 B. E. Sands, *Dig. Dis.*, 2014, **32**(supple 1), 74.
15 M. Allocca, M. Jovani, G. Fiorino, S. Schreiber and S. Danese, *Curr. Drug Targets*, 2013, **14**, 1508.
16 D. J. Gibson, E. J. Ryan and G. A. Doherty, *Inflammatory Bowel Dis.*, 2013, **19**, 2716.
17 K. Hasumi, S. Sato, T. Saito, J. Y. Kato, K. Shirota, J. Sato, H. Suzuki and S. Ohta, *Bioorg. Med. Chem.*, 2014, **22**, 4162.
18 N. Hayakawa, M. Noguchi and S. Takeshita, *et al.*, *Bioorg. Med. Chem.*, 2014, **22**, 3021.
19 W. J. Sandborn, S. Ghosh, J. Panes, I. Vranic, W. Wang and W. Neizychowski, *et al.*, *Clin. Gastroenterol. Hepatol.*, 2014, **12**, 1485.
20 G. Monteleone, M. F. Neurath and S. Ardizzone, *et al.*, *N. Engl. J. Med.*, 2015, **372**, 1104.
21 S. Banskota, H. E. Kang, D. G. Kim, S. W. Park, H. Jang, U. Karmacharya, B. S. Jeong, J. A. Kim and T. G. Nam, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 4587.
22 D. Thapa, J. S. Lee, S. Y. Park, Y. H. Bae, S. K. Bae, J. B. Kwon, K. J. Kim, M. K. Kwak, Y. J. Park, H. G. Choi and J. A. Kim, *J. Pharmacol. Exp. Ther.*, 2008, **327**, 353.
23 N. Kobayashi, A. Ikesue, S. Majumdar and T. J. Siahaan, *J. Pharmacol. Exp. Ther.*, 2006, **317**, 309.
24 S. Park, S. C. Regmi, S. Y. Park, E. K. Lee, J. H. Chang, S. K. Ku, D. H. Kim and J. A. Kim, *Eur. J. Pharmacol.*, 2014, **735**, 184.
25 A. R. Jurjus, N. N. Khoury and J. M. Reimund, *J. Pharmacol. Toxicol. Methods*, 2004, **50**, 81.
26 D. G. Kim, Y. Kang, H. Lee, E. K. Lee, T. G. Nam, J. A. Kim and B. S. Jeong, *Eur. J. Med. Chem.*, 2014, **78**, 126.
27 S. J. Yang, S. H. Lee, H. J. Kwak and Y. D. Gong, *J. Org. Chem.*, 2013, **78**, 438.
28 J. E. Krawisz, P. Sharon and W. F. Stenson, *Gastroenterology*, 1984, **87**, 1344.
29 E. Sekizuka, M. B. Grisham, M. A. Li, E. A. Deitch and D. N. Granger, *Gastroenterology*, 1988, **95**, 1528.

 This journal is © The Royal Society of Chemistry 2018